36358996|t|Possible Application of Melatonin in Long COVID.
36358996|a|Clinical sequelae and symptoms for a considerable number of COVID-19 patients can linger for months beyond the acute stage of SARS-CoV-2 infection, "long COVID". Among the long-term consequences of SARS-CoV-2 infection, cognitive issues (especially memory loss or "brain fog"), chronic fatigue, myalgia, and muscular weakness resembling myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are of importance. Melatonin may be particularly effective at reducing the signs and symptoms of SARS-CoV-2 infection due to its functions as an antioxidant, anti-inflammatory, and immuno-modulatory agent. Melatonin is also a chronobiotic medication effective in treating delirium and restoring the circadian imbalance seen in COVID patients in the intensive care unit. Additionally, as a cytoprotector, melatonin aids in the prevention of several COVID-19 comorbidities, including diabetes, metabolic syndrome, and ischemic and non-ischemic cardiovascular diseases. This narrative review discusses the application of melatonin as a neuroprotective agent to control cognitive deterioration ("brain fog") and pain in the ME/CFS syndrome-like documented in long COVID. Further studies on the therapeutic use of melatonin in the neurological sequelae of SARS-CoV-2 infection are warranted.
36358996	24	33	Melatonin	Chemical	MESH:D008550
36358996	37	47	Long COVID	Disease	MESH:D000094024
36358996	109	117	COVID-19	Disease	MESH:D000086382
36358996	118	126	patients	Species	9606
36358996	175	195	SARS-CoV-2 infection	Disease	MESH:D000086382
36358996	198	208	long COVID	Disease	MESH:D000094024
36358996	221	267	long-term consequences of SARS-CoV-2 infection	Disease	MESH:D000086382
36358996	269	278	cognitive	Disease	MESH:D003072
36358996	298	309	memory loss	Disease	MESH:D008569
36358996	314	323	brain fog	Disease	MESH:D005222
36358996	327	342	chronic fatigue	Disease	MESH:D015673
36358996	344	351	myalgia	Disease	MESH:D063806
36358996	357	374	muscular weakness	Disease	MESH:D018908
36358996	386	436	myalgic encephalomyelitis/chronic fatigue syndrome	Disease	MESH:D015673
36358996	438	444	ME/CFS	Disease	MESH:D015673
36358996	465	474	Melatonin	Chemical	MESH:D008550
36358996	543	563	SARS-CoV-2 infection	Disease	MESH:D000086382
36358996	609	621	inflammatory	Disease	MESH:D007249
36358996	652	661	Melatonin	Chemical	MESH:D008550
36358996	718	726	delirium	Disease	MESH:D003693
36358996	773	778	COVID	Disease	MESH:D000086382
36358996	779	787	patients	Species	9606
36358996	850	859	melatonin	Chemical	MESH:D008550
36358996	894	902	COVID-19	Disease	MESH:D000086382
36358996	928	936	diabetes	Disease	MESH:D003920
36358996	938	956	metabolic syndrome	Disease	MESH:D024821
36358996	962	1011	ischemic and non-ischemic cardiovascular diseases	Disease	MESH:D017202
36358996	1064	1073	melatonin	Chemical	MESH:D008550
36358996	1112	1135	cognitive deterioration	Disease	MESH:D003072
36358996	1138	1147	brain fog	Disease	MESH:D005222
36358996	1154	1158	pain	Disease	MESH:D010146
36358996	1166	1181	ME/CFS syndrome	Disease	MESH:D015673
36358996	1201	1211	long COVID	Disease	MESH:D000094024
36358996	1255	1264	melatonin	Chemical	MESH:D008550
36358996	1272	1296	neurological sequelae of	Disease	MESH:D009422
36358996	1297	1317	SARS-CoV-2 infection	Disease	MESH:D000086382
36358996	Negative_Correlation	MESH:D008550	MESH:D015673
36358996	Negative_Correlation	MESH:D008550	MESH:D017202
36358996	Negative_Correlation	MESH:D008550	MESH:D007249
36358996	Negative_Correlation	MESH:D008550	MESH:D003920
36358996	Negative_Correlation	MESH:D008550	MESH:D010146
36358996	Negative_Correlation	MESH:D008550	MESH:D024821
36358996	Negative_Correlation	MESH:D008550	MESH:D005222
36358996	Negative_Correlation	MESH:D008550	MESH:D000094024
36358996	Negative_Correlation	MESH:D008550	MESH:D003072
36358996	Negative_Correlation	MESH:D008550	MESH:D003693
36358996	Negative_Correlation	MESH:D008550	MESH:D009422
36358996	Negative_Correlation	MESH:D008550	MESH:D000086382

